Roche has alternatives to Illumina on its radar screen; Medicago inks $33M vaccines deal; Xoma sells shares for R&D work;

@FierceBiotech: Aragon Pharmaceuticals raises $42M for closely watched prostate #cancer drug. Article | Follow @FierceBiotech

@JohnCFierce: FierceMedicalDevices tracked the top VC device deals of H2 2011. Report | Follow @JohnCFierce

@MarkHFierce: Roche to Illumina: "You're not the only game in in town." In other words, the pressure mounts. Reuters Story | Follow @MarkHFierce

> Hoping to gain some leverage with Illumina's ($ILMN) board, Roche ($RHHBY) says that there are other potential buyout targets if its $5.7 billion hostile bid founders. Report

> Canada's Medicago says it has struck a $33 million deal to use its virus-like particle technology to develop new vaccines for Mitsubishi Tanabe. Release

> Xoma plans to sell shares in order to raise money for future R&D work as well as cover the cost of layoffs. Story

> CytomX Therapeutics named Dr. Hoyoung Huh as chairman of the board of directors. Former Chairman Dr. Charles Homcy, venture partner at Third Rock Ventures, will continue to serve on the board. Release

Pharma News

@FiercePharma: Facing new drug shortages, HealthCanada may bring in alternatives from overseas markets, CTV says. More | Follow @FiercePharma

> More reps sue Novo for back overtime. Story

> HHS: Misbehaving drugmakers could lose patent rights. Article

Research News

> UCLA's 'molecular tweezers' dismantles Parkinson's in zebra fish. More

> Canadian cancer funding targets radical projects. Item

> Breakthrough IDs possible liver repair process. Story

> Beefed-up FAK protein slashed heart attack damage in mice. Article

> The battle to halt Alzheimer's may come down to sugar. More

Manufacturing News

> Boehringer Ingelheim spends €17M on expansion in Germany, Vienna. News

> Novartis names new leader for its troubled OTC operations. Story

> India's Emcure to manufacture Roche's Herceptin, MabThera. Article

> AmerisourceBergen buys another pharmaceutical services company. Item

> GlaxoSmithKline, Daiichi Sankyo join forces to sell vaccines in Japan. More

And Finally… The Financial Times hits some familiar notes covering Big Pharma's increasing reliance on biotechs for innovative new treatments. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.